Outcomes of docetaxel and cisplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
10.3760/cma.j.issn.1004-4221.2012.01.006
- VernacularTitle:多西他赛加顺铂诱导化疗联合同期放化疗局部晚期非小细胞肺癌的临床观察
- Author:
Shuhong HAN
;
Xiaotao ZHANG
;
Xuesong WU
;
Zhen ZHANG
;
Chengye GUO
;
Xuezhen MA
;
Lan YU
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung/intensity-modulated radiotherapy;
Carcinoma,non-small cell lung/induction chemotherapy;
Carcinoma,non-small cell lung/concurrent chemoradiotherapy
- From:
Chinese Journal of Radiation Oncology
2012;21(1):16-19
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and side-effect of docetaxel and cisplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC).MethodsEighty-six patients with histologically confirmed locally advanced NSCLC were randomized into induction chemotherapy followed by concurrent chemoradiotherapy (ICCRT)arm or concurrent chemoradiotherapy (CCRT) arm. Both arms were treated with intensity-modulated radiation therapy. Induction and concurrent chemotherapy regimen consist of docetaxel and cisplatin. Results Follow-up rate of the whole group is 100％.The response rate in the CCRT arm and ICCRT arm is 70％ and 80％ ( χ2 =1.26,P =0.261 ),respectively; and 1-,2-,3-year survival rate is 65％ and 85％,40％ and 50％,33％ and 44％ (χ2 =3.90,P=0.048),respectively; the median survival time and time to progression is 17.5 and 22.0 months and 14.0 and 19.0 months respectively.Major adverse effects are leukopenia (43 and 32 cases,χ2 =3.48,P =0.062),radiation esophagutis (26 and 20 cases,χ2 =0.12,P =0.730),anemia (26 and 16 cases,χ2 =2.34,P =0.126) and radiation pneumonitis (13 and 9 cases,χ2 =0.37,P =0.541 ).ConclusionsICCRT for locally advanced NSCLC can improve the overall survival rate and time to progression,induction chemotherapy did not increase side-effects.There was no difference in response rate between CCRT and ICCRT arm.
